Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
POZEN third quarter revenue increases to $4.9 million

POZEN third quarter revenue increases to $4.9 million

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Janssen Biotech receives FDA approval for Remicade to treat UC in children

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers file lawsuit against Abbott in Texas state court

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN reports revenue of $4.6 million for second quarter 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Big news for ankylosing spondylitis sufferers

Big news for ankylosing spondylitis sufferers

New genetic research on Ankylosing Spondylitis

New genetic research on Ankylosing Spondylitis

New genetic clues about ankylosing spondylitis

New genetic clues about ankylosing spondylitis

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers file suit against Abbott Laboratories in federal court

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.